Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | HTT | P42858 | 5/20 | 0.74 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31058671 | 1.00 | MEN1 (1.00) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL23362057 | 0.85 | MEN1 (0.73) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL23362086 | 0.85 | MEN1 (0.73) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL23363354 | 0.85 | MEN1 (0.73) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL31734031 | 0.85 | MEN1 (0.73) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL31217463 | 0.83 | HTT (1.00) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL2957014 | 0.78 | MAPT (1.00) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL1877511 | 0.77 | F13A1 (0.70) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL900149 | 0.77 | HTT (0.77) | MEN1KMT2ALMNAHTTUSP2 | |
| SCHEMBL22129877 | 0.74 | ALDH1A1 (0.73) | MEN1KMT2AHTTPKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3900725-B1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | KOREA BASIC SCIENCE INST (KR) | 2024-08-28 | — | — | EP | claimed |
| US-20220218726-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | KOREA BASIC SCIENCE INSTITUTE (KR) | 2022-07-14 | — | — | US | claimed |
| WO-2020130696-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | 한국기초과학지원연구원 | 2020-06-25 | — | — | WO | claimed |
| EP-3900725-B1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | KOREA BASIC SCIENCE INST (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-20220218726-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | KOREA BASIC SCIENCE INSTITUTE (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220218726-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | KOREA BASIC SCIENCE INSTITUTE (KR) | 2022-07-14 | — | — | US | disclosed |
| EP-3900725-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | Korea Basic Science Institute (KR) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020130696-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | 한국기초과학지원연구원 | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218726-A1 | COMPOSITION COMPRISING CYP4A-INHIBITING COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING METABOLIC DISEASES | CYP4A11, CYP46A1, CYP27A1 | MEN1 3727/4885KMT2A 1568/4885LMNA 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.